A high rate of ceftobiprole resistance among clinical MRSA from a hospital in central Italy.

A high rate of ceftobiprole resistance among clinical MRSA from a hospital in central Italy.
Antimicrob Agents Chemother. 2018 Oct 01;:
Authors: Morroni G, Brenciani A, Brescini L, Fioriti S, Simoni S, Pocognoli A, Mingoia M, Giovanetti E, Barchiesi F, Giacometti A, Cirioni O
Abstract
Ceftobiprole is a fifth-generation cephalosporin with activity against MRSA. One-year surveillance at the Regional Hospital of Ancona (Italy) disclosed a 12% ceftobiprole resistance rate (12/102 isolates, MIC ≥4 mg/L). Epidemiological characterization demonstrated that the resistant isolates all belonged to different clones. PBP analysis showed substitutions in all PBPs and a novel insertion in PBP2a. Genes mecB and mecC were not detected. Ceftobiprole susceptibility screening is essential to avoid therapeutic failure and spread of ceftobiprole-resistant strains.
PMID: 30275082 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - October 1, 2018 Category: Microbiology Authors: Morroni G, Brenciani A, Brescini L, Fioriti S, Simoni S, Pocognoli A, Mingoia M, Giovanetti E, Barchiesi F, Giacometti A, Cirioni O Tags: Antimicrob Agents Chemother Source Type: research